alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2017104EN.01003901.xml

| 3.4.2017 | EN | Official Journal of the European Union | C 104/39 |
| --- | --- | --- | --- |

3.4.2017

EN

Official Journal of the European Union

C 104/39

---

Judgment of the General Court of 17 February 2017 — Islamic Republic of Iran Shipping Lines and Others v Council

(Joined Cases T-14/14 and T-87/14) (1)

1

((Common foreign and security policy - Restrictive measures taken against Iran with the aim of preventing nuclear proliferation - Freezing of funds - Plea of illegality - Legal basis - Misuse of powers - Rights of the defence - Legitimate expectations - Legal certainty - Ne bis in idem - Res judicata - Proportionality - Manifest error of assessment - Fundamental rights))

(2017/C 104/54)

Language of the case: English

Parties

Parties

Applicants: Islamic Republic of Iran Shipping Lines (Tehran, Iran) and 10 other parties (represented by: F. Randolph QC, P. Pantelis, Solicitor, M. Lester, Barrister, and M. Taher, Solicitor)

Applicants:

Defendant: Council of the European Union (represented by: M. Bishop and V. Piessevaux, acting as Agents)

Defendant:

Intervener in support of the defendant in Case T-87/17: European Commission (represented by: D. Gauci and T. Scharf, acting as Agents)

Intervener in support of the defendant in Case T-87/17:

Re:

Re:

Application, in Case T-14/14, pursuant to Article 263 TFEU, for annulment of Council Decision 2013/497/CFSP of 10 October 2013 amending Decision 2010/413/CFSP concerning restrictive measures against Iran (OJ 2013 L 272, p. 46), and of Council Regulation (EU) No 971/2013 of 10 October 2013 amending Regulation (EU) No 267/2012 concerning restrictive measures against Iran (OJ 2013 L 272, p. 1), in so far as those acts concern the applicants; and, in Case T-87/14, (i) pursuant to Article 277 TFEU, for a declaration that Decision 2013/497 and Regulation No 971/2013 are inapplicable, and (ii) pursuant to Article 263 TFEU, for annulment of Council Decision 2013/685/CFSP of 26 November 2013 amending Decision 2010/413/CFSP concerning restrictive measures against Iran (OJ 2013 L 316, p. 46), and of Council Implementing Regulation (EU) No 1203/2013 of 26 November 2013 implementing Regulation (EU) No 267/2012 concerning restrictive measures against Iran (OJ 2013 L 316, p. 1), in so far as those acts concern the applicants.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the actions; |
| --- | --- |

1.

Dismisses the actions;

| 2. | Orders Islamic Republic of Iran Shipping Lines and the other applicants whose names are listed in the Annex to bear their own costs and to pay those incurred by the Council of the European Union; |
| --- | --- |

2.

Orders Islamic Republic of Iran Shipping Lines and the other applicants whose names are listed in the Annex to bear their own costs and to pay those incurred by the Council of the European Union;

| 3. | Orders the European Commission to bear its own costs. |
| --- | --- |

3.

Orders the European Commission to bear its own costs.

---

(1)  OJ C 71, 8.3.2014.

1

---
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from IDS Managed
Futures II, L.P. for the second quarter of 1999 and is qualified in its entirety
by reference to such 10-Q.
</LEGEND>
<CIK> 0000813831
<NAME> IDS MANAGED FUTURES II, L.P.

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               JUN-30-1999
<CASH>                                      11,560,382
<SECURITIES>                                         0
<RECEIVABLES>                                   33,787
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            11,594,169
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              11,594,169
<CURRENT-LIABILITIES>                          221,431
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  11,372,738
<TOTAL-LIABILITY-AND-EQUITY>                11,594,169
<SALES>                                              0
<TOTAL-REVENUES>                             1,254,242
<CGS>                                                0
<TOTAL-COSTS>                                  251,101
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              1,003,141
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          1,003,141
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,003,141
<EPS-BASIC>                                      60.39
<EPS-DILUTED>                                    60.39


</TABLE>
### SAT Report PMN Number: P-10-0246 SAT Date: 5/21/2010 Print Date: 4/20/2011

Related cases : CBI : Yes Health related cases : Ecotox related cases:

Concern levels : Type of Concern: Health Eco Comments Level of Concern: 2 1

Persistence Bioaccum Toxicity Comments 3 31

Exposure Based Review : Health: Ecotox: N o
Routes of exposure : Health: Dermal Inhalation Ecotox: N o releases to water Fate: ; Keywords : Keywords: LUNG OVERLOAD; ONCO; IMMUNOTOX; MUTA (UNCERT)
Summary of Assessment :
Fate : Fate Summary: P-10-0246 FATE: Solid with MP = Dec. 499 C (M) S < 0.001 mg/L at 25 C (E) VP < 1.0E-6 torr at 25 C (E) BP > 400 C (E) H < 1.00E-8 (E) POTW removal (%) = 0-90 via sorption Time for complete ultimate aerobic biodeg > moSorption to soils/sediments = low - v.strong PBT Potential: P3B3 *CEB FATE: Migration to ground water = negl – rapid Direct photolysis will be negl - rapid Indirect photolysis will be negl - rapid

Health : Health Summary: Expect poor absorption via all routes ( p che m /analog). Concern for lung toxicity if inhaled based on lung overload for poorly soluble particulates. Also concern for oncogenicity and immunotoxicity based on carbon nanomaterials. Uncertain concern for mutagenicity.

Ecotox :

Test Organism Test Type Test End Point Predicted Measured Comments

fish 96-h LC50 * daphnid 48-h LC50 * green algal 96-h EC50 * fish

_ chronic value * daphnid

_ chronic value * algal

_ chronic value * Sewage Sludge 3-h EC50

_ Sewage Sludge

_ Chronic Value

_ Ecotox Values Comments: Predictions are based on SARs for nonionic polymers; SAR chemical class = p olyme r -nonionic-carbon; MW > 1,000,000; p H7; effective concentrations based on 100% active ingredients and nominal concentrations; hardness <180.0 mg/L as CaCO3; and TOC <2.0 mg/L;

Factors Values Comments Assessment Factor 10 Concentration of Concern ( p pb) *

SARs nonionic polymers SAR Class p olyme r -nonionic-carbon allotrope

Ecotox Factors Comments:

SAT Chair: L Keifer 564-8916
1 Pursuant to 5th Cir. R. 47.5, the Court has determined that this opinion should not be

published and is not precedent except under the limited circumstances set forth in 5th Cir. R. 47.5.4. -1- United States Court of Appeals Fifth Circuit 

## FILED March 8, 2004 Charles R. Fulbruge III Clerk UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

_________________________ No. 03-31026 SUMMARY CALENDAR

_________________________ WILFRED T. LABORDE; PAUL TIMOTHY LABORDE; PATRICK J. LABORDE; DAVE T. LABORDE,

Plaintiffs - Appellants

v. BROWN & WILLIAMSON TOBACCO CORPORATION; PHILIP MORRIS INCORPORATED, doing business as Phillip Morris USA INC.; R.J. REYNOLDS TOBACCO COMPANY, INC.,

Defendants - Appellees.

______________________________________________________________________________

On Appeal from the United States District Court for the

Middle District of Louisiana (00-CV-388-D)

______________________________________________________________________________ Before REYNALDO G. GARZA, HIGGINBOTHAM, and DeMOSS, Circuit Judges. REYNALDO G. GARZA, Circuit Judge: 1 In this appeal, we review the district court's decision granting Defendants - Appellees’, Brown & Williamson Tobacco Corporation, Philip Morris Incorporated, and R.J. Reynolds Tobacco Company, application for taxation of costs.-2-

Appellants argue that the application for taxation of costs should have been denied because Uniform Local Civil Rule 54.3 requires that the application be filed within 30 days of entry of a final judgment, and Appellees’ application was filed 31 days after the entry of judgment. However, we agree with the district court and find that the application was timely filed. Uniform Local Civil Rule 54.3 actually requires that an application for taxation of costs be filed 30 days after receiving notice of entry of judgment. The district court entered judgment on May 20, 2003. As required by FED. R. CIV. P 77(d), the district clerk served the notice of entry of judgment by mail and facsimile the same day in the manner provided for in Rules 5(b)(2)(B) and (D). Because the notice of entry of judgment was served by mail and facsimile, FED. R. CIV. P. 6(e) granted Appellees three additional days in which to file their application for taxation of costs. The application was filed on June 20, 2003, 31 days after judgment was entered. Thus, it was timely. For the foregoing reasons, the judgment of the district court is affirmed.
# C_2014315EN.01004201.xml

| 15.9.2014 | EN | Official Journal of the European Union | C 315/42 |
| --- | --- | --- | --- |

15.9.2014

EN

Official Journal of the European Union

C 315/42

---

Request for a preliminary ruling from the Amtsgericht Rüsselsheim (Germany) lodged on 14 July 2014 — Elvira Mandl, Helmut Mandl v Condor Flugdienst GmbH

(Case C-337/14)

2014/C 315/68

Language of the case: German

Referring court

Referring court

Amtsgericht Rüsselsheim

Parties to the main proceedings

Parties to the main proceedings

Applicants: Elvira Mandl, Helmut Mandl

Applicants:

Defendant: Condor Flugdienst GmbH

Defendant:

Question referred

Question referred

Is there an obligation on an airline company which wishes to rely on the possibility of exemption in Article 5(3) of Regulation No 261/2004 (1) to set out and prove that it took all reasonable measures to avoid the foreseeable consequences of an extraordinary circumstance in the form of cancellation or considerable delay or that no such reasonable measures were available to it?

1

---

(1)  Regulation (EC) No 261/2004 of the European Parliament and of the Council of 11 February 2004 establishing common rules on compensation and assistance to passengers in the event of denied boarding and of cancellation or long delay of flights, and repealing Regulation (EEC) No 295/91 — Commission Statement (OJ 2004 L 46, p. 1).

1

---
§ 803.33 If I am a user facility, what must I include when I submit an annual report? ( a ) You must submit to us an annual report on Form FDA 3419. You must submit an annual report by January 1, of each year. You may obtain this form on the internet at: *https://www.fda.gov/media/72292/download .*
( b ) You must clearly identify your annual report as such. You must submit your annual report to FDA, CDRH, Medical Device Reporting, P.O. Box 3002, Rockville, MD 20847-3002. Your annual report must include: ( 1 ) Your CMS provider number used for medical device reports, or the number assigned by us for reporting purposes in accordance with § 803.3;
( 2 ) Reporting year;
( 3 ) Your name and complete address;
( 4 ) Total number of reports attached or summarized;
( 5 ) Date of the annual report and report numbers identifying the range of medical device reports that you submitted during the report period (e.g., 1234567890-2011-0001 through 1000);
( 6 ) Name, position title, and complete address of the individual designated as your contact person responsible for reporting to us and whether that person is a new contact for you; and
( 7 ) Information for each reportable event that occurred during the annual reporting period including: ( i ) Report number;
( ii ) Name and address of the device manufacturer;
( iii ) Device brand name and common name;
( iv ) Product model, catalog, serial, and lot number and unique device identifier (UDI) that appears on the device label or on the device package;
( v ) A brief description of the event reported to the manufacturer and/or us; and
( vi ) Where the report was submitted, i.e., to the manufacturer, importer, or us.
( c ) In lieu of submitting the information in paragraph (b)(7) of this section, you may submit a copy of each medical device report that you submitted to the manufacturers and/or to us during the reporting period.
( d ) If you did not submit any medical device reports to manufacturers or us during the time period, you do not need to submit an annual report.
[79 FR 8846, Feb. 14, 2014, as amended at 80 FR 10587, Feb. 27, 2015; 85 FR 18442, Apr. 2, 2020]
§ 524.770 Doramectin. ( a ) *Specifications.* Each milliliter (mL) of solution contains 5 milligrams (mg) doramectin.
( b ) *Sponsors.* See Nos. 051072 and 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.222 of this chapter.
( d ) *Special considerations.* See § 500.25 of this chapter.
( e ) *Conditions of use in cattle* — ( 1 ) *Amount.* Administer topically 1 mL (5 mg doramectin) per 22 lb (10 kg) of body weight.
( 2 ) *Indications for use.* For treatment and control of gastrointestinal roundworms: *Ostertagia ostertagi* (adults and fourth-stage larvae), *Ostertagia ostertagi* (inhibited fourth-stage larvae), *Ostertagia lyrata* (adults), *Haemonchus placei* (adults and fourth-stage larvae), *Trichostrongylus axei* (adults and fourth-stage larvae), *Trichostrongylus colubriformis* (adults and fourth-stage larvae), *Cooperia oncophora* (adults and fourth-stage larvae), *Cooperia punctata* (adults and fourth-stage larvae), *Cooperia pectinata* (adults), *Cooperia surnabada* (adults), *Bunostomum phlebotomum* (adults), *Oesophagostomum radiatum* (adults and fourth-stage larvae), *Trichuris spp.* (adults); lungworms: *Dictyocaulus viviparus* (adults and fourth-stage larvae); eyeworms: *Thelazia gulosa* (adults), *Thelazia skrjabini* (adults); grubs: *Hypoderma bovis* and *Hypoderma lineatum*; sucking lice: *Linognathus vituli*, *Haematopinus eurysternus*, and *Solenopotes capillatus*; biting lice: *Bovicola (Damalinia) bovis*; mange mites: *Chorioptes bovis* and *Sarcoptes scabiei*; horn flies: *Haematobia irritans*; and to control infections and to protect from reinfection with *Cooperia oncophora*, *Dictyocaulus viviparus*, *Ostertagia ostertagi*, and *Oesophagostomum radiatum* for 28 days; and with *Cooperia punctata* and *Haemonchus placei* for 35 days after treatment; and to control infestations and to protect from reinfestation with *Linognathus vituli* for 42 days and with *Bovicola (Damalinia) bovis* for 77 days after treatment.
( 3 ) *Limitations.* Cattle must not be slaughtered for human consumption within 45 days of treatment. Not for use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.
[69 FR 48392, Aug. 10, 2004, as amended at 70 FR 43046, July 26, 2005; 79 FR 10967, Feb. 27, 2014; 84 FR 32993, July 11, 2019; 87 FR 10970, Feb. 28, 2022; 88 FR 27700, May 3, 2023]
§ 610.18 Cultures. ( a ) *Storage and maintenance.* Cultures used in the manufacture of products shall be stored in a secure and orderly manner, at a temperature and by a method that will retain the initial characteristics of the organisms and insure freedom from contamination and deterioration.
( b ) *Identity and verification.* Each culture shall be clearly identified as to source strain. A complete identification of the strain shall be made for each new stock culture preparation. Primary and subsequent seed lots shall be identified by lot number and date of preparation. Periodic tests shall be performed as often as necessary to verify the integrity of the strain characteristics and freedom from extraneous organisms. Results of all periodic tests for verification of cultures and determination of freedom from extraneous organisms shall be recorded and retained.
( c ) *Cell lines used for manufacturing biological products* — ( 1 ) *General requirements.* Cell lines used for manufacturing biological products shall be: ( i ) Identified by history;
( ii ) Described with respect to cytogenetic characteristics and tumorigenicity;
( iii ) Characterized with respect to in vitro growth characteristics and life potential; and
( iv ) Tested for the presence of detectable microbial agents.
( 2 ) *Tests.* Tests that are necessary to assure the safety, purity, and potency of a product may be required by the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research.
( 3 ) *Applicability.* This paragraph applies to diploid and nondiploid cell lines. Primary cell cultures that are not subcultivated and primary cell cultures that are subsequently subcultivated for only a very limited number of population doublings are not subject to the provisions of this paragraph (c).
( d ) *Records.* The records appropriate for cultures under this section shall be prepared and maintained as required by the applicable provisions of §§ 211.188 and 211.194 of this chapter.
[38 FR 32056, Nov. 20, 1973, as amended at 51 FR 44453, Dec. 10, 1986; 55 FR 11013, Mar. 26, 1990; 67 FR 9587, Mar. 4, 2002; 70 FR 14985, Mar. 24, 2005]
<PAGE>   1
                                                                    EXHIBIT 23.3

                       CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the use in this Registration Statement on Form S-1/A of our
report dated April 24, 1998, except for the first paragraph of Note 9 which is
as of August 27, 1999, relating to the financial statements of Arcxel
Technologies, Inc., which appears in such Registration Statement. We also
consent to the references to us under the headings "Experts" and "Selected
Financial Data" in such Prospectus.


PricewaterhouseCoopers LLP
Seattle, Washington
August 27, 1999
#### § 814.108 Supplemental applications.

After FDA approval of an original HDE, an applicant shall submit supplements in accordance with the requirements for PMA's under § 814.39, except that a request for a new indication for use of a HUD shall comply with requirements set forth in § 814.110. The timeframes for review of, and FDA action on, an HDE supplement are the same as those provided in § 814.114 for an HDE.

[63 FR 59220, Nov. 3, 1998]
### Fi;_(INCOURTOFAPPEALS 12thCourtofAppeals District

OFFICIAL NOTICE FROM COURT OF CRIMINAL APPEALS OF TEXAS P.O. BOX 12308, CAPITOL STATION, AUSTIN, TEXAS 78711

8/7/2015 COA Case No. 12-14-00125-CR WRIGHT, JEFFREYDOCK Tr. Ct. No. 241-1880-13 PD-1007-15 

### On this day, this Court has granted the Appellant's Pro Se motion for an extension of time in which to file the Petition for Discretionary Review. The time to file the 

### petition has been extended to Monday, September 07, 2015. NO FURTHER EXTENSIONS WILL BE ENTERTAINED. NOTE: Petition For Discretionary Review must be filed with The CourtofCriminal Appeals. Abel Acosta, Clerk

12TH COURT OF APPEALS CLERK CATHY LUSK 1517 W. FRONT, ROOM 354 TYLER, TX 75701

* DELIVERED VIA E-MAIL * FILE COPY
# C_2014303EN.01001101.xml

| 8.9.2014 | EN | Official Journal of the European Union | C 303/11 |
| --- | --- | --- | --- |

8.9.2014

EN

Official Journal of the European Union

C 303/11

---

Request for a preliminary ruling from the Kecskeméti Közigazgatási és Munkaügyi Bíróság (Hungary) lodged on 27 May 2014 — Robert Michal Chmielewski v Nemzeti Adó- és Vámhivatal Dél alföldi Regionális Vám- és Pénzügyőri Főigazgatósága

(Case C-255/14)

2014/C 303/15

Language of the case: Hungarian

Referring court

Referring court

Kecskeméti Közigazgatási és Munkaügyi Bíróság

Parties to the main proceedings

Parties to the main proceedings

Applicant: Robert Michal Chmielewski

Applicant:

Defendant: Nemzeti Adó- és Vámhivatal Dél alföldi Regionális Vám- és Pénzügyőri Főigazgatósága

Defendant:

Questions referred

Questions referred

| 1) | Does the amount of the fine imposed by Paragraph 5/A of Law XLVIII of 2007 implementing Regulation (EC) No 1889/2005 of the European Parliament and of the Council of 26 October 2005 on controls of cash entering or leaving the Community (1) (‘the national implementing law’) fulfil the requirement in Article 9(1) of that Regulation, according to which the penalties laid down by national law must be effective, dissuasive and, at the same time proportionate to the infringement and to the objective pursued?... |
| --- | --- |

1)

Does the amount of the fine imposed by Paragraph 5/A of Law XLVIII of 2007 implementing Regulation (EC) No 1889/2005 of the European Parliament and of the Council of 26 October 2005 on controls of cash entering or leaving the Community (1) (‘the national implementing law’) fulfil the requirement in Article 9(1) of that Regulation, according to which the penalties laid down by national law must be effective, dissuasive and, at the same time proportionate to the infringement and to the objective pursued?...

1

| 2) | Does Paragraph 5/A of the national implementing law not infringe, as a result of the amount of the fines it provides for, the prohibition on disguised restrictions on the free movement of capital in the Treaty on European Union and in Article 65(3) of the Treaty on the Functioning of the European Union? |
| --- | --- |

2)

Does Paragraph 5/A of the national implementing law not infringe, as a result of the amount of the fines it provides for, the prohibition on disguised restrictions on the free movement of capital in the Treaty on European Union and in Article 65(3) of the Treaty on the Functioning of the European Union?

---

(1)  OJ 2005 L 309, p. 9.

1

---